Development and Validation of a Predictive Model for Nonadherence with Once-Daily Glaucoma Medications
Development and Validation of a Predictive Model for Nonadherence with Once-Daily Glaucoma Medications
复制标题
DOI：
10.1016/j.ophtha.2013.01.002
复制
发表时间：
2013-07-01
期刊：
影响因子：
13.7
通讯作者：
Boland, Michael V.
中科院分区：
文献类型：
--
作者：
Chang, Dolly S.;Friedman, David S.;Boland, Michael V.
目的：为了开发和验证一个预测模型，以估计不遵守局部青光眼medications.Design的概率：前瞻性队列study.Participants：患者正在与每日一次的前列腺素滴眼液治疗。使用来自自动给药提醒研究（ADRS; n = 407）的单独受试者队列评估TDA衍生模型的性能。该评估基于回归系数、区分度和校准。我们还开发了一个评分系统，从TDA衍生的模型，以简化临床使用的风险估计。主要结果Measures：滴使用电子监测3个月，在这两项研究。依从性计算为该患者在平均给药时间4小时内接受给药的天数百分比。不依从定义为服用
Objective: To develop and validate a predictive model to estimate the probability of being nonadherent to topical glaucoma medications.Design: Prospective cohort study.Participants: Patients being treated with once-daily prostaglandin eye drops.Methods: A predictive model for nonadherence was developed from the Travatan Dosing Aid (TDA) study (n = 196) using stepwise logistic regression. The performance of the TDA-derived model was assessed using a separate cohort of subjects from the Automated Dosing Reminder Study (ADRS; n = 407). The assessment was based on regression coefficients, discrimination, and calibration. We also developed a scoring system from the TDA-derived model to simplify the estimation of risk for clinical use.Main Outcome Measures: Usage of drops was monitored electronically for 3 months in both studies. Adherence was calculated as the percentage of days on which a dose was taken within 4 hours of the average dosing time for that patient. Nonadherence was defined as taking